Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 10/20 | 0.47 |
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17847387 | 0.86 | MYC (0.55) | HTR1DSLC6A4RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12948034 | 0.76 | KDM4E (0.51) | RAB9ANPC1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL28639617 | 0.76 | KDM4E (0.44) | RAB9ANPC1SMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL9422430 | 0.76 | CA1 (0.65) | RAB9ANPC1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL15714702 | 0.74 | MYC (0.71) | RAB9ANPC1SMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL12918700 | 0.73 | TDP1 (0.65) | RAB9ANPC1SMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL5202186 | 0.73 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL19639503 | 0.73 | RARA (0.51) | SMN1; SMN2KDM4EGSK3AGSK3BMAPT | |
| SCHEMBL12920437 | 0.72 | MAPT (0.53) | RAB9ANPC1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL12920436 | 0.72 | MAPT (0.53) | RAB9ANPC1SMN1; SMN2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | claimed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | claimed |
| EP-3233806-B1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RES & DEV (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | disclosed |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-05-12 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342040-A1 | NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS | RARA, RARB, RARG | HTR1D 3421/4885SLC6A4 4676/4885RAB9A 2985/4885 |
| US-10647688-B2 | Compounds, synthesis method thereof and use of same in medicine and in cosmetics | RARA, RARB, RARG | HTR1D 3538/4885SLC6A4 4598/4885RAB9A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.